Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 8/20 | 0.39 |
| ▸ | CTSD | P07339 | 8/20 | 0.39 |
| ▸ | CTSE | P14091 | 8/20 | 0.39 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | MMP8 | P22894 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17526955 | 0.95 | BACE1 (0.41) | BACE1CTSDCTSEABCB1 | |
| SCHEMBL18463911 | 0.90 | BACE1 (0.37) | BACE1CTSDCTSEABCB1 | |
| SCHEMBL1709985 | 0.90 | BACE1 (0.38) | BACE1CTSDCTSEABCB1 | |
| SCHEMBL23109986 | 0.90 | BACE1 (0.39) | BACE1CTSDCTSEABCB1MMP2 | |
| SCHEMBL31634286 | 0.85 | ALDH1A1 (0.41) | BACE1CTSDCTSE | |
| SCHEMBL27742237 | 0.85 | BACE1 (0.39) | BACE1CTSDCTSEABCB1 | |
| SCHEMBL31634285 | 0.84 | ALDH1A1 (0.40) | BACE1CTSDCTSEABCB1 | |
| SCHEMBL22966090 | 0.84 | BACE1 (0.35) | BACE1CTSDCTSEABCB1MMP2 | |
| SCHEMBL21843036 | 0.84 | BACE1 (0.36) | BACE1CTSDCTSE | |
| SCHEMBL16549357 | 0.83 | BACE1 (0.38) | BACE1CTSDCTSE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | S&T GLOBAL INC. | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170101445-A1 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | HAVCR2, TSLP, HLA-DRB1 | BACE1 2791/4885CTSD 1375/4885CTSE 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.